BAYLOR COLLEGE OF MEDICINE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1900-10-30
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.bcm.edu
Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage
Phase 3
Completed
- Conditions
- Abscess
- Interventions
- Drug: oral trimethoprim/sulfamethoxazoleDrug: Placebo
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 23
- Registration Number
- NCT00691600
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
A Comparison of Renal Perfusion in Thoracoabdominal Aortic Aneurysm (TAAA) Repair
Not Applicable
Completed
- Conditions
- Renal Failure
- Interventions
- Procedure: Cold blood renal perfusionProcedure: Cold crystalloid renal perfusion
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 172
- Registration Number
- NCT00691756
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Study of Selected X-linked Disorders: Goltz Syndrome
Active, not recruiting
- Conditions
- Focal Dermal Hypoplasia (FDH)Goltz Syndrome
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 84
- Registration Number
- NCT00691223
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Understanding Sleep Problems in Children With Autism Spectrum Disorder
Completed
- Conditions
- Sleep Problems
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2016-01-13
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 58
- Registration Number
- NCT00691080
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
🇺🇸Oregon Health & Sciences University, Portland, Oregon, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Phase 4
Completed
- Conditions
- Peripheral Arterial Disease
- Interventions
- Drug: Statin therapyBehavioral: Standard careDrug: Placebo NiaspanProcedure: Percutaneous transluminal angioplasty (PTA)
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 102
- Registration Number
- NCT00687076
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Phase 1 Intrathecal Topotecan for Neoplastic Meningitis
Phase 1
Completed
- Conditions
- Neoplastic Meningitis
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 22
- Registration Number
- NCT00674674
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Folate Rechallenge
Phase 2
Completed
- Conditions
- Autism
- Interventions
- Dietary Supplement: Folic acidDietary Supplement: Placebo
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT00672360
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Physiological Disturbances Associated With Neonatal Intraventricular Hemorrhage
Not Applicable
Terminated
- Conditions
- Intraventricular HemorrhageAutoregulation
- Interventions
- Other: NormocapniaOther: Hypercapnia
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 103
- Registration Number
- NCT00665769
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Safety and Effectiveness of Soy Phytoestrogens to Prevent Bone Loss
Not Applicable
Completed
- Conditions
- Osteoporosis
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: Soy isoflavones
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 403
- Registration Number
- NCT00665860
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸University of Georgia, Athens, Georgia, United States
🇺🇸University of California, Davis, California, United States
Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation
Phase 4
Terminated
- Conditions
- End-stage Liver DiseaseRenal FailureRenal Insufficiency
- Interventions
- Other: placebo medication
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT00656266
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath